Published on
May 23, 2024
In the media
91ÌÒÉ« Therapeutics raises €46 million Series B to develop disease-modifying therapies for autoimmune disorders
About 91ÌÒÉ« Therapeutics
â€
91ÌÒÉ« Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology to guide the immune system. 91ÌÒÉ« approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. 91ÌÒÉ« are progressing first-in-class antigen modulators to treat people living with cancers, autoimmune disorders, and infectious diseases.
â€
91ÌÒÉ« is headquartered in Oxford, UK.
â€
More information: 91ÌÒÉ«bsite |
â€
Media enquiries
Patrick White, Head of Communications
â€
